Who
Steven George Hughes
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Atrium Therapeutics; Chief Medical Officer, Avidity Biosciences; Chief Development Officer, Arcturus Therapeutics Holdings; Chief Medical Officer, VivoSim Labs.
In numbers
- Trades disclosed
- 62
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $5.4M
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 14 Aug 2018
- Last trade
- 18 Sep 2026
- Last filed
- 22 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 22 Sep 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code F | $192K21,459 at $8.95 | filing |
| 18 Sep 2026filed 22 Sep 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code F | $192K21,459 at $8.95 | filing |
| 20 Apr 2026filed 22 Apr 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | RNA Atrium TherapeuticsBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —115,857 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —73,342 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —74,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —73,342 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —74,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —49,333 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —68,458 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —49,333 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —68,458 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciences | SEC FORM 4 Code D | —115,857 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $146K2,017 at $72.45 | filing |
| 21 Jan 2026filed 23 Jan 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Sold | $209K2,878 at $72.45 | filing |
News
Charles River Laboratories International (NYSE:CRL) versus VivoSim Labs (NASDAQ:VIVS) Head-To-Head ContrastVIVS · dailypolitical.com · 22 Oct 2026VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker ProfilingVIVS · manilatimes.net · 21 Oct 2026
0 headlines in the last 90 days name Steven George Hughes; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.